Skip to content
  • Home
  • About Us
    • How we work
    • Our People
      • Executive Team
      • OG Network
    • Case Studies
  • Industry Groups
    • Financial Services
    • Corporate & Public
  • Services
    • Services & Capabilities
    • Advisory
    • Assurance
      • Risk Assurance
      • s166 “Skilled Person” Reviews
      • Audit Effectiveness
    • Consultancy
      • Brexit
      • Regulation, Control, Risk & Compliance
      • Business & Product Development
      • Transformation Management
      • Corporate Governance
      • Conduct & Culture
      • Leadership Lab
      • Programme Office
    • Expert Witness
      • Key Expert Services
      • Litigation Support
      • Case Management
    • Resourcing Hub
  • News Room
  • Contact
    • Contact Us
    • Skilled Person Review Enquiries
    • OG Network Registration

Corporate Advisory

December 16, 2016January 1, 2017

Actavis UK accused of overcharging NHS for vital drug

Actavis UK has been accused of overcharging the NHS for a “lifesaving” drug by raising the price by more than 12,000%

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Related

Categories: Uncategorized Tags: Good Conduct Author: Jason Sumner

Post navigation

Previous Post Six pharmaceutical firms accused of price-fixing
Next Post Australian court increases fine over ‘misleading’ Nurofen
  • Twitter
  • LinkedIn
  • Google +
  • Terms of Use
  • Privacy Policy
  • Legal & Regulatory
  • Corporate Responsibility
  • Mission, Vision & Values
  • Site Map
  • © 2018 OCREUS Group
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptReject Read More
Privacy & Cookies Policy